Results 11 to 20 of about 4,569 (190)

Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancerResearch in context

EClinicalMedicine, 2023
Summary: Background: Radium-223, a targeted alpha therapy, is approved to treat bone-dominant metastatic castration-resistant prostate cancer (mCRPC), based on significantly prolonged overall survival versus placebo and a favourable safety profile in ...
Celestia S. Higano, Daniel J. George, Neal D. Shore, Oliver Sartor, Kurt Miller, Peter S. Conti, Cora N. Sternberg, Fred Saad, Juan Pablo Sade, Joaquim Bellmunt, Matthew R. Smith, Kumari Chandrawansa, Per Sandström, Frank Verholen, Bertrand Tombal   +14 more
doaj   +1 more source

Radium-223 as an Additional Therapeutic Strategy in Highly Selected Patients With Metastatic Breast Cancer: A Case Report

Frontiers in Oncology, 2022
Radium-223 is commonly used in metastatic prostate cancer, targeting specifically bone metastases. The use of radium-223 remains, however, poorly evaluated in metastatic breast cancer.
Hélène Houssiau, Francois P. Duhoux, Didier François, Emmanuel Seront   +3 more
doaj   +1 more source

Radium-223 for metastatic, castration-resistant prostate cancer: A retrospective chart review study of real-world use in a tertiary hospital in Taiwan

Journal of the Formosan Medical Association, 2022
Background: Radium-223 is an alpha-emitting, bone-targeting radiopharmaceutical that confers a survival benefit in patients with confirmed bone-metastatic, castration-resistant prostate cancer with no visceral metastases.
Wei-Chun Weng, Li-Hua Huang, Neng-Chuan Tseng, Yen-Chuan Ou   +3 more
doaj   +1 more source

Radium‐223 dichloride treatment in metastatic castration‐resistant prostate cancer in Finland: A real‐world evidence multicenter study

Cancer Medicine, 2023
Background Radium‐233 dichloride is an alpha emitter that specifically targets bone metastases in prostate cancer. Results of a previously reported phase III randomized trial showed survival benefit for radium‐223 compared to best supportive care in ...
Anniina Hyväkkä, Okko‐Sakari Kääriäinen, Tapio Utriainen, Eliisa Löyttyniemi, Kalle Mattila, Petri Reinikainen, Jorma Sormunen, Minna Jääskeläinen, Päivi Auvinen, Heikki Minn, Maria Sundvall   +10 more
doaj   +1 more source

Alpha emitter radium-223 in patients with metastatic castration-resistant prostate cancer: A cost-utility analysis

Frontiers in Pharmacology, 2022
Objective: To assess the cost effectiveness of radium-223 dichloride for patients with metastatic castration-resistant prostate cancer (mCRPC) in China.Materials and methods: A Markov model was developed to estimate the long-term health and economic ...
Xiaohui Zeng, Qiao Liu, Chongqing Tan, Xiaomin Wan, Yunhua Wang, Xiaowei Ma   +5 more
doaj   +1 more source

Histopathology of castration-resistant prostate cancer confirms changes in bone metastasis during radium-223 treatment: A case report

Urology Case Reports, 2020
Radium-223 is used for treating castration-resistant prostate cancer with bone metastases. Here, we report the case of a 76-year-old man diagnosed with castration-resistant prostate cancer with bone metastases who was started on radium-223.
Masato Dobashi, Dai Kouguchi, Yukiko Kanetsuna, Junichiro Ishii   +3 more
doaj   +1 more source

Optimal usage of radium-223 in metastatic castration-resistant prostate cancer

Journal of the Formosan Medical Association, 2017
Radium-223 is a first-in-class α-emitting radiopharmaceutical that targets bone metastases associated with metastatic castration-resistant prostate cancer (mCRPC).
Tai-Lung Cha, Tony Tong-Lin Wu, Nicholas John Vogelzang, Chao-Yuan Huang, Shu-Pin Huang, Chia-Chi Lin, Yen-Chuan Ou, See-Tong Pang, Daniel Heung-Yuan Shen, Wen-Jeng Wu, Wayne Yen-Hwa Chang   +10 more
doaj   +1 more source

Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer.

PLoS ONE, 2019
BackgroundRadium-223 is a targeted alpha-particle therapy that improves survival in men with metastatic castration resistant prostate cancer (mCRPC), particularly in men with elevated serum levels of bone alkaline phosphatase (B-ALP).
Andrew J Armstrong, Santosh Gupta, Patrick Healy, Gabor Kemeny, Beth Leith, Michael R Zalutsky, Charles Spritzer, Catrin Davies, Colin Rothwell, Kathryn Ware, Jason A Somarelli, Kris Wood, Thomas Ribar, Paraskevi Giannakakou, Jiaren Zhang, Drew Gerber, Monika Anand, Wen-Chi Foo, Susan Halabi, Simon G Gregory, Daniel J George   +20 more
doaj   +1 more source

A phase II randomized trial of metastasis-directed therapy with alpha emitter radium-223 in men with oligometastatic castration-resistant prostate cancer (MEDAL)

BMC Urology, 2023
Background The significance of metastasis-directed therapy for oligometastatic prostate cancer has been widely discussed, and targeted therapy for progressive sites is a feasible option as a multidisciplinary treatment for castration-resistant prostate ...
Soichiro Yoshida, Taro Takahara, Yuki Arita, Masaya Ito, Sara Hayakawa, Tomohiko Oguchi, Yoshinobu Komai, Noboru Numao, Takeshi Yuasa, Masaharu Inoue, Hiroki Ushijima, Shigehiro Kudo, Yasumasa Shimano, Yuki Nakamura, Yusuke Uchida, Sho Uehara, Hajime Tanaka, Hiroshi Yaegashi, Kouji Izumi, Minato Yokoyama, Yoh Matsuoka, Yasuo Yoshioka, Koji Konishi, Katsuyuki Nakanishi, Akira Nagahara, Akihiro Hirakawa, Ryuji Koike, Fumitaka Koga, Kazuo Nishimura, Atsushi Mizokami, Junji Yonese, Yukio Kageyama, Ryoichi Yoshimura, Yasuhisa Fujii   +33 more
doaj   +1 more source

Circulating tumor cells and γH2AX as biomarkers for responsiveness to radium-223 in advanced prostate cancer patients

Future Science OA, 2020
Aim: Radium-223 improves overall survival in patients with metastatic castration-resistant prostate cancer to the bone. Radium-223 causes double-strand DNA breaks and produces γH2AX, a potential biomarker for response.
Jonathan Chatzkel, Jesse Mocha, Johnna Smith, Jun-Min Zhou, Youngchul Kim, Ghassan El-Haddad, Jingsong Zhang   +6 more
doaj   +1 more source